U.S. Markets closed

Reata's drug, Bardoxolone, shows promising results for chronic kidney disease

Reata is in its 'final pivotal study' for its new drug, bardoxolone. In the trials, the drug has showed promising results to reverse kidney damage. Yahoo Finance sits down with the CEO of Reata, Warren Huff, who founded the company in 2002, to discuss the plans to launch the product in the near future.